Highlights

  • Syntara has widened its Phase 1b scar study from 20 to 30 participants and added a second Sydney site.
  • Top-line results from the expanded study are anticipated in the first quarter of 2027.
  • A separate keloid study has reported preliminary tissue-level findings at Week 12.
  • Clinical measures in that study showed no observable differences, alongside some skin reactions.

Syntara Limited (ASX:SNT) has provided an update on two clinical programs targeting scarring conditions. The first is the SNT-9465 Phase 1b study in hypertrophic sternotomy scars, where recruitment of the initial cohort is nearing completion and the study has been expanded to 30 participants. The second is the exploratory SATELLITE study of SNT-6302 in keloid scars, which has now reported preliminary findings from six participants who completed twelve weeks of treatment. The two updates show different stages of clinical development and carry different kinds of information. This article outlines each program and what the company has reported.

Phase 1b Study of SNT-9465 Expands

The SNT-9465 Phase 1b study is double-blind and placebo-controlled, and it is investigating hypertrophic scars that follow sternotomy surgery. Recruitment for the initial 20-participant cohort is nearing completion, and the company has expanded the study to 30 participants. An additional site, The Skin Hospital in Sydney, has also been added.

The study is designed to assess safety and tolerability, along with exploratory biological and clinical activity. Top-line results are expected in the first quarter of 2027. In the announcement, CEO Gary Phillips indicated that expanding the study at this stage is very cost effective and is expected to deliver more reliable results in that quarter. A double-blind design means neither participants nor investigators know who receives the active treatment, which helps limit bias when comparing against placebo.

SATELLITE Study in Keloid Scars

The SATELLITE study is an exploratory trial of SNT-6302 in keloid scars, conducted with the University of Western Australia and the Fiona Wood Foundation. Six participants completed 12 weeks of treatment. The company reported a preliminary increase in blood-vessel area density at Week 12, which it noted aligns with findings from the earlier SOLARIA2 study in hypertrophic scars.

Keloid scars are raised scars that extend beyond the boundary of the original wound, and they are generally considered harder to treat than other scar types. Because the SATELLITE study is exploratory and the number of completing participants is small, the findings are best read as early signals rather than conclusions. The announcement frames them as preliminary, and further analysis would be needed to understand their significance.

Interpreting the Mixed Preliminary Findings

The SATELLITE update contains more than one kind of result. Alongside the blood-vessel observation, the company reported no observable differences in POSAS scores or scar stiffness at Week 12. POSAS is a scoring tool that combines observer and patient assessments of scar quality, so the absence of observable differences is a relevant data point for the exploratory objectives.

The announcement also notes that eight participants discontinued due to mild reversible local skin reactions, specifically erythema and pruritus, meaning redness and itching. Taken together, the updates describe a program at an early and exploratory stage, where tolerability and biological activity are being examined before any conclusions about clinical benefit can be drawn. Readers may wish to follow the Phase 1b results in 2027 for further information.

Key Takeaways

Syntara's update covers two scar-focused programs at different points of progress. The SNT-9465 Phase 1b study has been enlarged to 30 participants, supported by an additional Sydney site, with top-line results expected in the first quarter of 2027. The exploratory SATELLITE study of SNT-6302 in keloid scars reported a preliminary rise in blood-vessel area density at Week 12, no observable differences in POSAS scores or scar stiffness, and eight discontinuations because of mild reversible skin reactions. Both programs remain early stage, and the company's disclosures describe exploratory objectives rather than confirmed clinical outcomes. Further data are required before any conclusions can be reached.